Effect of spironolactone on impaired fibrinolysis of hypertensive patients.
OBJECTIVE
Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists have beneficial effects on impaired fibrinolytic activity of hypertensive patients. The aim of the study was to evaluate the effect of antialdosterone treatment on impaired fibrinolysis of hypertensive patients.


METHODS
Fourteen hypertensive outpatients and 14 normotensive healthy volunteers participated in this study. Blood samples for plasminogen activator inhibitor-1 (PAI-1) antigen and tissue plasminogen activator (t-PA) antigen were obtained at baseline in all patients and control subjects. Then all hypertensive patients used spironolactone 50 mg/day for a week. Blood samples were again obtained after a week of spironolactone treatment.


RESULTS
The mean basal plasma level of PAI-1 of hypertensive patients was higher than those of the normotensive control group (60.98 +/- 4.2 vs. 24.09 +/- 1.61 ng/ml, p < 0.01) The mean basal t-PA level was similar in the hypertensive and control subjects (7.49 +/- 0.65 vs. 8.78 +/- 0.92 ng/ml, p > 0.05). The mean PAI-1 level decreased after a week of spironolactone treatment (60.98 +/- 4.2 vs. 42.99 +/- 7.98 ng/ml, p < 0.05). The mean plasma t-PA level of hypertensive patients increased after spironolactone treatment (7.49 +/- 0.65 vs. 11.09 +/- 1.33 ng/ml, p < 0.05).


CONCLUSIONS
This study shows that spironolactone improves impaired fibrinolysis in systemic hypertension. It provides evidence for a direct link between aldosterone and the fibrinolytic system in humans.
Yalcin
Ahmet Igir
AI
Department of Nephrology, Osmangazi University Medical School, TR-26010 Eskisehir, Turkey. auyalcin@ogu.edu.tr
Dincer
Murat
M
Aslan
Vahap
V
Gulbas
Zafer
Z
D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000378:metabolism; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D013148:Spironolactone / Q000627:therapeutic use*; D010959:Tissue Plasminogen Activator / Q000378:metabolism
D000451:Mineralocorticoid Receptor Antagonists; D017395:Plasminogen Activator Inhibitor 1; D013148:Spironolactone; D000450:Aldosterone; D010959:Tissue Plasminogen Activator